Table 2 Analysis between MGMT hypermethylation and NSCLC different clinicopathological features.
Analysis | Studies N | Methylation N(+/−) | OR(95% CI) | Method | Heterogeneity | P value | |
|---|---|---|---|---|---|---|---|
I 2 (%) | P value | ||||||
NSCLC | 20 | 476/2115 | 4.60 [3.46, 6.11] | Fixed | 47 | 0.01 | <0.00001 |
age | 5 | 180/405 | 1.21 [0.83, 1.77] | Fixed | 32 | 0.21 | 0.31 |
sex | 13 | 491/976 | 0.83 [0.65, 1.06] | Fixed | 42 | 0.05 | 0.14 |
smoking | 12 | 533/873 | 1.29 [0.73, 2.28] | Random | 72 | <0.00001 | 0.39 |
pathological types | 15 | 497/970 | 0.80 [0.63, 1.01] | Fixed | 21 | 0.22 | 0.06 |
differentiation | 4 | 115/238 | 2.02 [0.89, 4.55] | Random | 51 | 0.11 | 0.09 |
clinical stage | 14 | 491/953 | 0.77 [0.59, 0.99] | Random | 50 | 0.02 | 0.04 |
